Breaking Down Allogene Therapeutics: 5 Analysts Share Their Views
Breaking Down Allogene Therapeutics: 5 Analysts Share Their Views
分解异基因疗法：5 位分析师分享了他们的观点
Throughout the last three months, 5 analysts have evaluated Allogene Therapeutics (NASDAQ:ALLO), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 2 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 2 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $9.92, a high estimate of $17.00, and a low estimate of $4.60. This current average has increased by 48.06% from the previous average price target of $6.70.
Deciphering Analyst Ratings: An In-Depth Analysis
A comprehensive examination of how financial experts perceive Allogene Therapeutics is derived from...
登录免费看全文
登录/注册